Rohtak News Magazine

Creative Biolabs Ready to Support Complement-Based Drug Discovery

 Breaking News
  • No posts were found

Creative Biolabs Ready to Support Complement-Based Drug Discovery

August 23
18:56 2022
Through more than a decade of scientific exploration, Creative Biolabs is now well positioned to offer a range of complement-related services and products.

New York, USA – August 23, 2022 – The complement system is an essential part of innate immunity, thus bridging innate and adaptive immunity. It is closely associated with a variety of diseases, from infections, immune system disorders, to tumors.

In recent years, with the in-depth study of the complement system as well as the continuous development of molecular biology techniques, the development of the drug targeting complement system has become gradually active – involving a variety of complement system-related diseases.

Overall, there are three complement system pathways: the classical pathway, the lectin pathway, and the alternative pathway.

The classical pathway is a major contributor to the defense against infection, clearance of pathogens, and maintenance of homeostasis. At least 21 different serum proteins have been identified as components of the classical pathway, with 11 major proteins playing the most critical roles.

The classical pathway mediates a variety of autoimmune and inflammatory diseases and therefore requires strict regulation in order to prevent unnecessary complement activation. Complement inhibitors can antagonize excessive complement activation and render potential clinical applications. Scientists have identified a series of inhibitors that target proteins of the classical pathway, such as C1q, C1r, and C3.

The alternative pathway is a branch of the complement network, and it is widely acknowledged as a crucial component in recognizing and eliminating pathogens via direct killing or phagocytosis stimulation.

Unlike the classical pathway, the alternative pathway can be activated automatically. The alternative pathway is the complement activation pathway that begins directly from C3 and does not require antigen-antibody complexes or the activation of C1, C2, and C4.

With a focus on the alternative pathway, Creative Biolabs provides a series of therapeutic antibodies, inhibitors, and soluble complement regulators to meet various needs for research.

Creative Biolabs has established a comprehensive complement platform that offers a series of complement-related products most efficiently and cost-effectively.

For various complement components, modulators, receptors, and complement agglutinin pathway targets, Creative Biolabs offers the following products: antibodies, proteins, assay kits, peptides, inhibitors, sera, vectors, lysates, reagents, and aptamers.

Find out more about Creative Biolabs’ complement-related services and products at https://www.creative-biolabs.com/complement-therapeutics.

About Creative Biolabs

As a leading biological company, Creative Biolabs is confident in its continued role in complement-based drug development. At Creative Biolabs, a wide range of services are offered for complement therapies, and project design can be customized to meet specific requirements.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/complement-therapeutics

Related Articles